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The search for cancer treatment continues to be a global eﬀort. As part of this global eﬀort, many natural products have been
tested against cancer cell lines, mostly from tropically located plants. This study reports that extracts of Atriplex confertifolia (Torr.
and Frem.) S. Watson (Chenopodiaceae), a native North American plant (also known as shadscale or saltbush), has signiﬁcant
bioactivity against human breast cancer cell lines MCF-7, MDA-MB 435, MDA-MB 231, and HeLa cells (cervical cancer cells).
The bioactivity of A. confertifolia extracts on these cells lines was compared to an FDA-approved cancer drug (Onxol)a n da n
industry-standardleukocytecontrolcellline.Activeportionsoftheextractswerefoundprimarilyinthepolarfractionsoftheplant.
A dose-response curve of the extracts displayed signiﬁcant cell death similar to Onxol. The plant extracts did not signiﬁcantly
inhibit the viability of the leukocyte cell line. In a timed study, over 90% of cell lines MDA-MB 435 and HeLa died after 24 hours.
Cell death appears to result from apoptosis.
1.Introduction
In 2008, 565,000 Americans died of cancer. Cancer is the
second most common cause of death in the US, exceeded
only by heart disease [1]. Pollner [2] reported that cancer
in the United States has more than doubled in the last 30
years, from 1 in 20 in 1960 to 1 in 9 today. Although cancer
is not the number one cause of mortality in the United States
it is often painful, and is the most feared of diseases [3].
Therefore, the search for cancer treatments will continue
until a cure is found.
In the past 10 years new technology has provided
additional therapies. For example, imaging technology has
delivered tomosynthesis [4] and advances in genetics have
produced a variety of antiangiogenesis drugs. However, as
Bettelheim [5] noted, “The war on cancer isn’t just fought
with bioengineered drugs and souped-up genes. Scientists
also utilize ornamental shrubs, tree bark, sea horses, and
thousands of other natural products that serve as the basis
for new cancer drugs.”
Each year thousands of plant extracts are screened for
bioactivity against cancer [5]. Most botanical investigations
have come from rainforest or tropical plants, yet there are
many untested nontropical plants and a few have shown
bioactivity [6, 7]. One such example is Taxol, the number
one selling cancer drug, which is derived from Paciﬁc yew
tree bark. Though, its initial discovery was not enthusi-
astically endorsed by the medical community, its success
has precipitated an intensive search for new natural prod-
uct treatments. Other plant-derived drugs that have been
discovered include topotecan, vincristine, and vinblastine
[5].
ABrighamYoungUniversity(BYU)studywascompleted
in 2001 to screen more than 40 plants of North America for
their cytotoxicity [8]. One of the plants, Atriplex confertifolia
(Torr. and Frem.), S. Watson (Chenopodiaceae), showed
much greater bioactivity than others. This plant (also known
as shadscale or saltbush) is widely distributed throughout
North America from Texas to North Dakota and west to
the Paciﬁc Ocean. The majority of studies on A. confertifolia2 Journal of Toxicology
have been focused on its distribution [9], lifespan [10],
botanical and ecological characteristics [11]a n dh o wi th a s
beenaﬀectedbygrazing[12].Nostudieshadbeenperformed
on the bioactivity of A. confertifolia until 2004, when Welch
[13] determined the cytotoxicity eﬀects of A. confertifolia on
human cervical cancer cells (HeLa cells).
A. confertifolia is known to provide a source of palatable,
nutritious forage for a wide variety of wildlife and livestock.
Speciﬁcally, the fruits and leaves are a food source for deer,
desert bighorn sheep, pronghorn, small rodents, jackrabbits,
game birds, and songbirds [14]. Of all Atriplex genera in
North America, A. confertifolia is ecologically the most
important and can grow on a greater variety of soils. Welch
[13] found that the most bioactive fraction of A. confertifolia
killed more than 94% of the HeLa cells in a laboratory
bioassay. “The fact that A. confertifolia is edible but still
kills cancer cells may be very important. It suggests that
the cytotoxic agents in the plant may show speciﬁcity only
towards cancerous cells, making it an excellent candidate for
pharmacological use [13].” From the positive cytotoxicity
results of Welch’s study using HeLa cells, it was thought that
A. confertifolia may have bioactivity on other human cancer
cells.
2.MaterialsandMethods
2.1. Source of Plant Material. All procedures used the same
samples of Atriplex confertifolia that were taken west of
Lehi, Utah (40◦ 13  51   N, 112◦ 11  33   W) and stored at
4◦C in a cold room at Brigham Young University (BYU).
Collection of Atriplex confertifolia (Torr. and Frem.) S.
Watson (Chenopodiaceae) was performed by Gary M. Booth
on July 2004 as voucher specimen number 0001. This plant
was deposited as a voucher specimen at the Stanley L. Welch
Herbarium at Brigham Young University and identiﬁcation
was conﬁrmed by curators at the herbarium.
2.2. Isolation
2.2.1. Extraction and Bilayer Separation. The leaves, stems,
and branches of A. confertifolia were cut or chopped into
2.5cmorsmallerpiecesandthenfurtherhomogenizedusing
a common mortar and pestle. Approximately 23g of crude,
dry plant material were added to a 250mL Erlenmeyer Flask.
Then 130mL of methanol were added to the ﬂask and
the mixture was stirred on a stir plate for 24 hours. This
methanol solution was then ﬁltered using Whatman No. 30
(11.0cm) ﬁlter paper and the supernatant was retained.
Approximately 3mL of the methanol/Atriplex extraction
were placed into a 15mL screw-cap conical test tube. This
was followed by the addition of 3mL of distilled water to
the test tube and then 3mL of hexane. The test tube was
then tightly capped and shaken vigorously for 20 seconds.
This was usually done with a sequence of four test tubes at
a time. These test tubes were then centrifuged for 5 minutes
at 1500 rpm. The polar methanol/water portions dissolved
the polar compounds, while hexane dissolved the nonpolar
compounds, resulting in an aqueous hexane bi-layer. The
hexane fraction formed the upper phase in the test tube. The
hexane was then pipetted from the methanol /water portion
using a standard Pasteur pipette.
2.2.2. Cell Culture Lines. The following cell lines were
o b t a i n e df r o mA T C CT h eG l o b a lB i o r e s o u r c eC e n t e r[ 15]
a n dw e r eu s e di nt h ec u r r e n ts t u d y :A T C Cn u m b e rH T B -
22 designation of MCF-7 was established from pleural
eﬀusion from a 69-year-old female with adenocarcinoma
[16]. MCF-7 cells were recommended as target cells because
oftheirwidelyacknowledgedestrogensensitivity[17].ATCC
number HTB-26 designation of 231, adenocarcinoma of
human breast mammary gland was obtained from a 51-year-
old female. MD Anderson number MDA-MB designation of
435, adenocarcinoma of human breast mammary gland was
obtained from a 31-year-old female. ATCC number CCL-2
designationofHeLawasanadenocarcinomaepithelialcellof
the cervix obtained from a 31-year-old female [15]. Finally,
normal human lymphocyte cells, speciﬁcally monocytes,
from a healthy 28-year-old male were used as a control.
Population doubling times for the MCF-7, MDA-MB 435,
MDA-MB 231, and HeLa cell lines were estimated at 36, 16,
24–36, and ∼80 hours, respectively [18–20].
2.2.3. Nonpolar and Polar Extracts. A bioassay was then
performed using each cell line to determine which portion
showed cytotoxicity. The bioassay was performed in the
following manner:
a 2mL volume of the methanol/water portion was added
to a 2mL Eppendorf tube (microcentrifuge tube) and 2mL
of the hexane were added to another 2mL Eppendorf
tube. These tubes were allowed to evaporate to dryness. A
volume of 300μL of Roswell Park Memorial Institute 1640
(RPMI1640), which is the cell growth medium, was then
addedtoeachEppendorftube.Thesetubeswerethencapped
and thoroughly mixed using a sonicator (Cole-Parmer 8851)
and a deluxe mixer (Scientiﬁc Products).
Av o l u m eo f4 0 μL of each sample was then added to
each of three wells in a 96-well ﬂat-bottom plate that was
prepared with a cell solution with a concentration of 0.8–
1×105 cells/mL. Volumes of 50μL each of RPMI1640 were
alsoaddedtoatotalof9wellsintheplatetoserveascontrols.
The plate was allowed to incubate for 24 hours and then
stained with a sulforhodamine stain.
Living cells were stained while dead cells were washed
away. Once the cells were stained they were read using a
BioTek EL800 spectroﬂuorometer at 570nm. The number
of viable cells in the control wells was then compared to
the number in the wells treated with the methanol/water
and with the hexane portions of the A. confertifolia extrac-
tion/separation. The cytotoxic fraction was then detected by
ﬁnding which portion showed the lowest cell viability.
2.2.4. Dose-Response. The dose response curve was obtained
by the following procedure:
once the fraction from the column that showed the
highest degree of cytotoxicity was identiﬁed using the cellJournal of Toxicology 3
bioassay described in the isolation procedure above, it was
placed in a pre-weighed 2mL Eppendorf tube and allowed
to evaporate. Small portions of the cytotoxic fraction were
then added to the Eppendorf tube and allowed to evaporate
in this fashion until approximately 9mg of the A. confer-
tifolia extract were dried in the bottom of the Eppendorf
tube.
Atotalof1mLofRPMI1640wasaddedtothecompletely
dry A. confertifolia extract in the Eppendorf tube and
thoroughly mixed with a sonicator (Cole-Parmer 8851) and
a deluxe mixer (Scientiﬁc Products) so that all of the dry
A. confertifolia extract was in solution, resulting in an A.
confertifolia concentration of 9mg/mL. Volumes of 50μL
of normal RPMI1640 was then added to three wells in a
previously prepared 96-well ﬂat-bottomed plate where each
well had 150μLo fa0 .8–1 × 105 cells/mL solution. This
represented a dosage of 0mg permL. Normal RPMI1640
were also added to 9 other wells on the plate as the control
for the experiment.
A total of 45μL of the normal RPMI1640 was then added
to three wells of the plate. To these same three wells, 5μL
of the treated RPMI1640 were added. This gave these three
wells a total concentration of 0.23mg/mL. The calculated
concentration takes into account that 150μL of RPMI1640
had been added to each well when the cells were originally
added to the plate. Thus, the total liquid volume in each well
was now 200μL. In the next three wells, 40μLo fn o r m a l
RPMI1640 were added, and 10μL of the treated RPMI1640
was also added to create a concentration of 0.46mg/mL.
This pattern was continued until 50μLo ft r e a t e d
RPMI1640 was placed in each of three wells with no
normal RPMI1640. Those wells resulted in a concentration
of 2.28mg/mL. Three more wells containing 45μL of the
normal RPMI1640 were prepared. To these same three
wells, 5μL of diluted treated RPMI1640 were added. This
step was continued until concentrations of 0.12, 0.06, and
0.03mg/mL were obtained. This 96-well plate was then incu-
bated for 24 hours and then subjected to the sulforhodamine
staining procedure so that the viability of the cells could be
measured. These data were then plotted graphically as dose-
response curves. The data were transformed to the log scale
and analyzed using a linear mixed model program [21]. A
ﬁrst-order model, second-order model and a separate means
model were then ﬁtted.
2.2.5. FDA-Approved Drug Comparison. Dose-response
curves from the A. confertifolia extracts were then compared
to the chemotherapy drug Onxol dose response curves
obtained by the following procedure:
Onxol drug comes in liquid form at a concentration
of 4mg/mL. Volumes of 50μL of normal RPMI1640 were
then added to three wells in a previously prepared 96-well
ﬂat-bottomed plate where each well had 150μL of a 0.8-
1x105 cells/mL solution. This represented a control dosage of
0mg/mL. Normal RPMI1640 was also added to 9 other wells
on the plate as another control for the experiment.
A total of 45μL of the normal RPMI1640 was added to
three wells of the plate. To these same three wells, 5μLo f
the Onxol were added. This gave these three wells a total
concentration of 0.15mg/mL. The calculated concentration
takes into account that 150μL of RPMI1640 had been added
to each well when the cells were originally added to the plate.
The total liquid volume in each well was now 200μL.
A total of 40μL of normal RPMI1640 were added to the
next three wells, and then 10μL of the Onxol was added
to create a concentration of 0.30mg/mL. This pattern was
continued until 50μLo fOn x o l  wereplacedineachof three
wells with no normal RPMI1640. This gave those wells a
concentration of 1.52mg/mL.
To three more wells, 45μL of the normal RPMI1640 were
added. To these same three wells, 5μL of diluted Onxol
were added. This step was continued until concentrations
of 0.08, 0.04, and 0.02mg/mL were obtained. This 96-well
plate was then incubated for 24 hours and subjected to the
sulforhodaminestainingproceduresothattheviabilityofthe
cells could be measured.
2.2.6. Timed Response. The timed response curve was ob-
tained by the following procedure:
once the fraction from the column that showed the
highest degree of cytotoxicity was identiﬁed using the cell
bioassay described in the isolation procedure above, it was
placed in a pre-weighed 2mL Eppendorf tube and allowed
to evaporate. Small portions of the cytotoxic fraction were
then added to the Eppendorf tube and allowed to evaporate
inthisfashionuntilapproximately9mgoftheA.confertifolia
extract were dried in the bottom of the Eppendorf tube.
Atotalof1mLofRPMI1640wasaddedtothecompletely
dry A. confertifolia extract in the Eppendorf tube and
thoroughly mixed with a sonicator (Cole-Parmer 8851) and
a deluxe mixer (Scientiﬁc Products) so that all of the dry
A. confertifolia extract was in solution, resulting in an A.
confertifolia concentration of 9mg/mL. Volumes of 50μL
of normal RPMI1640 were then added to three wells in a
previously prepared 96-well ﬂat-bottomed plate where each
well had 150μL of a 0.8–1×105 cells/mL solution. This
represented a dosage of 0mg permL. Normal RPMI1640 was
also added to 9 other wells on the plate as the control for the
experiment.
Volumes of 15 μL of the normal RPMI1640 were added
to three wells of the plate. To these same three wells, 35μL
of the treated RPMI1640 were added. This gave these three
wells a total concentration of 1.59mg/mL. The 96-well plate
was then incubated for 1 hour and then subjected to the
sulforhodamine staining procedure. Another 96-well plate
thathadbeenpreparedinthesamefashionwasincubatedfor
2 hours and then subjected to the sulforhodamine staining
procedure. Also a third 96-well plate prepared in a similar
manner was incubated for 4 hours and then subjected to
the sulforhodamine staining procedure. This procedure was
continued at increments of 2 hours up to 24 hours from the
time the ﬁrst treated RPMI1640 was added. These data were
then plotted graphically as time-response curves. The data
were transformed to the log scale and analyzed using a linear
mixed model program [21]. A ﬁrst-order model was then
used to ﬁt the data.4 Journal of Toxicology
0
20
40
60
80
100
120
140
C
e
l
l
v
i
a
b
i
l
i
t
y
(
%
)
435 HeLa 231 MCF-7
Non polar
Polar
Figure 1: Bioactivity of the nonpolar and polar extracts of Atriplex
confertifolia against three human breast cancer cell lines (435, 231,
and MCF-7) and a human cervical cancer cell line (HeLa).
2.2.7. Cell Preparation for Scanning Electron Microscopy. The
scanning electron microscopy images were obtained by the
following procedure:
once the fraction from the column that showed the
highest degree of cytotoxicity was identiﬁed using the cell
bioassay described in the isolation procedure above, it was
placed in a pre-weighed 2mL Eppendorf tube and allowed
to evaporate. Small portions of the cytotoxic fraction were
then added to the Eppendorf tube and allowed to evaporate
inthisfashionuntilapproximately9mgoftheA.confertifolia
extract were dried in the bottom of the Eppendorf tube.
Atotalof1mLofRPMI1640wasaddedtothecompletely
dry A. confertifolia extract in the Eppendorf tube and
thoroughly mixed with a sonicator (Cole-Parmer 8851) and
a deluxe mixer (Scientiﬁc Products) so that all of the dry
A. confertifolia extract was in solution, resulting in an A.
confertifolia concentration of 9mg/mL. Volumes of 3mL
of solution of 0.8–1×105 cells/mL were pipetted onto on
each of two microscope slides. A total of 1mL of normal
RPMI1640 was added to one slide as a control for the
experiment, and onemL of treated RPMI1640 was added to
theotherslide.Thesewerelefttoincubatefor6–8hours.The
slides were then subjected to a routine SEM preparation.
HeLa cells were prepared for imaging using a Scanning
Electron Microscope (SEM) model Philips XL30 ESEM FEG
located at the Cluﬀ Building, BYU.
3. Results andDiscussion
Atriplex confertifolia was ﬁrst shown to contain bioactive
compounds during a cooperative study between BYU and
the New York Botanical Garden [13]. Figure 1 shows in a
similar manner that the bioactive component(s) of the A.
confertifolia are found primarily in the polar methanol/water
portion of the extraction. The polar fraction killed about
90% of the cells on all cell lines, while the nonpolar hexane
fraction only reduced cell viability by less than 20%.
These results are similar to the study reported by Welch
[13], but are in contrast to the work done by Donaldson
[22] who, while doing HeLa cell bioassays, found that
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Figure 2: Comparison of the dose-response curves for extracts
of Atriplex confertifolia against three human breast cancer cell
lines; 435, 231, MCF-7, HeLa, and normal human lymphocyte
(monocyte).
Atriplex canescens showed activity against HeLa cells with
hexane fractions (48.7% cell inhibition), but no activity with
methanol fractions (0.9% cell inhibition). However, Davis
[23]clearlydemonstratedthatmethanolfractionsweremore
toxicthanhexanefractionswhentestedagainstawidevariety
of plants on HeLa cells and 3T3 ﬁbroblasts as a control line.
When the A. confertifolia extracts fromthe active fraction
wereadministeredatdiﬀerentconcentrationstothecelllines,
cell viability showed a dose-response. The doses ranged from
0.03mg/mL to 2.28mg/mL. Cancer cell viability ranged, on
average, from 95 to ≤10% after exposing the cell lines to
varying concentrations of the A. confertifolia compounds
for 24 hours. The extract was apparently highly selective
since the monocyte control cells were aﬀected very little by
the extract (Figure 2). Comparing full and 2nd-order log
linear data models by a lack of ﬁt test gives a χ2 =12.1 and
a P≤.001, demonstrating the 2nd-order log linear model
is a preferred model. Similar data were found comparing
1st-order log linear and 2nd-order log linear χ2 =63.3 and
a P ≤.05.
Overall there were signiﬁcant diﬀerences among the
curves (F = 16.97, P ≤.0001). Among the four cancer cell
lines, there were also signiﬁcant diﬀerences for all pairs of
lines, with the smallest F = 5.50, and largest P=.0043. These
dose-response curves are similar to those reported by Lau
et al. [24], who used multiple pancreatic adenocarcinoma
cell lines to study the anticancer eﬀects of the fruit Brucea
javanica. They reported a dose range of 0.1μg/mL to
1000μg/mL and a cell survival rate of 90% to 20% after
exposing the cells to the active compound for 72 hours.
Medina-Hogu´ ın [25] showed that root oils of a desert plant
Anemopsis californica had antiproliferative activity against
AN3CA and HeLa cells in vitro but no activity against lung,Journal of Toxicology 5
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Figure 3: Toxicity of Onxol to human breast cancer cell lines 435,
231, and MCF-7.
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Figure 4: Timed toxicity response of cell lines 435, HeLa, and
monocyte control to 2.05mg/mL of extract from Atriplex confer-
tifolia.
breast, prostate or colon cancer cells. Hence, A. confertifolia
also showed activity against a variety of cell lines.
After the dose reached a concentration of approximately
1.59mg/mL, the cell viability leveled oﬀ at approximately
10%. This plateau is seen in other dose-responses listed in
the literature also. For example, the dose-response curves
reported by Sadeghi-Aliabadi and Ahmadi [26] started to
plateau at about 20% cell viability.
The toxicity data from the A. confertifolia extracts
(Figure 2) are similar to the dose-response curves gener-
ated using the chemotherapeutic drug Onxol (Paclitaxel)
(Figure 3). These data clearly show Onxol has excellent
cytotoxicity, with a signiﬁcant dose response (F = 8.51,
p<.0001) that diﬀered among cell lines (F = 1.71, P=.0315).
For Onxol, lower concentrations (0.3mg/mL) cause near
100% mortality. Gangadevi and Muthumary [27]h a v e
shown similar ﬁndings, wherein Paclitaxel caused about
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Figure 5: Scanning electron micrograph (SEM) of two normal
HeLa cancer cells.
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Figure 6: Scanning electron micrograph of a HeLa cell treated with
extracts of Atriplex confertifolia showing the formation of apoptotic
bodies.
80% apoptosis in each of ﬁve cell lines. Although the A.
confertifolia extract did not elicit the exact same dose-
response curves, it did show a similar degree of toxicity in
the higher doses as shown in Figure 2.
We may also take into consideration that extracts of A.
confertifolia have not been puriﬁed to single compounds,
which are causing cell death. With future isolation proce-
dures a more potent concentration of A. confertifolia might
be obtained resulting in even higher levels of toxicity at even
lower doses than the currently FDA-approved drugs.
To examine cell viability over time, a dose of 2.05mg/mL
was administered to a breast cancer cell line (435), a cervical
cancer cell line (HeLa), and the control monocyte cell line.
This dose was chosen because it typically demonstrated over
90% mortality. These cultures were allowed to incubate
from 1 to 24 hours. After 8 hours of incubation, cancer
cell viability decreased precipitously especially for the breast
cancer cells (Figure 4). Again, monocyte control cells did not
appear to be greatly aﬀected. After 18 hours of incubation,
both cancer cell cultures were reduced to approximately 20%
viability. There were signiﬁcant diﬀerences among all three
curves(F =168.89,P<.0001).However,thereisnostatistical
diﬀerence between the cancer cell lines (T = −0.9, P=.93).6 Journal of Toxicology
Many chemotherapy drugs, such as Paclitaxel and
colchicines, interfere with the normal function of micro-
tubule breakdown. Colchicine causes the depolymerization
of microtubules whereas Paclitaxel arrests their function by
having the opposite eﬀect; it hyper-stabilizes their structure.
This destroys the cell’s ability to use its cytoskeleton in a
ﬂexible manner and does not have the ability to disassemble.
This adversely aﬀects cell function because the shortening
and lengthening of microtubules (termed dynamic insta-
bility) is necessary for their function as a mechanism to
transport other cellular components [28]. It is possible that
A. confertifolia could be acting in a similar manner. However,
only additional experimentation could demonstrate that
aﬀect.
The delay in toxicity shown in Figure 4 suggests that it
takesapproximately8hoursforthetoxiccompoundstoenter
thecellthusresultingindeatheitherbyapoptosisornecrosis.
Apoptosis is controlled cell death while necrosis is the
immediate complete breakdown of the plasma membrane,
resulting in the release of intercellular proinﬂammatory
molecules [29].
Figure 5 shows an SEM of two normal HeLa cells, while
Figure 6 shows a HeLa cell treated with 2.05mg/mL of A.
confertifolia for 6–8 hours. The contorted-looking state of
the treated cell in Figure 6 shows cellular blebbing and the
formation of apoptotic bodies. The blebbing is an irregular
bulge in the plasma membrane typical of a cell undergoing
apoptosis.ThesebulgesnotedinFigure 6oftenseparatefrom
thecell,takingaportionofthecytoplasmwiththem[29,30].
Hence, these data suggest that A. confertifolia kills HeLa cells
by apoptosis and not by necrosis.
In conclusion, our publication data suggests that extracts
of A. confertifolia may cause cell death in three types of
breast cancer cells and a cervical cancer cell line (HeLa), but
does not aﬀect monocyte control cells. It is clear that the
majority of toxic compounds are found in the polar fractions
of this plant extract. The toxicity of A. confertifolia and
the concentration of the extracts were generally comparable
to those of the FDA-approved drug Onxol especially at
the highest doses, although Onxol killed the cells more
completely at lower doses. In addition, these data also show
it takes approximately 8–10 hours before cell mortality
can be detected. This was observed for both breast and
cervical cancer cells. The monocyte control culture was again
not aﬀected by the 24 hours incubation period with A.
confertifolia. Thus it is clear that extracts of A. confertifolia
causes cell death via apoptosis and not by necrosis. A.
confertifoliaisoneofthefewnontropicaldesertspeciestested
to date that shows selective bioactivity against a variety of
human cancer cells.
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